{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T18:10:27Z","timestamp":1773079827572,"version":"3.50.1"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,14]]},"DOI":"10.7759\/cureus.101555","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T23:59:07Z","timestamp":1768435147000},"source":"Crossref","is-referenced-by-count":1,"title":["Amantadine Toxicity Mimicking Holmes Tremor Following Diuretic Dose Escalation: A Case Report"],"prefix":"10.7759","author":[{"given":"Akio","family":"Nakashima","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motoyasu","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuko","family":"Tachikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osamu","family":"Imakyure","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-94-4-454","article-title":"Pharmacokinetics of amantadine hydrochloride in subjects with normal and impaired renal function","volume":"94","author":"Horadam VW","year":"1981","unstructured":"Horadam VW, Sharp JG, Smilack JD, et al.. Pharmacokinetics of amantadine hydrochloride in subjects with normal and impaired renal function. Ann Intern Med. 1981, 94:454-8. 10.7326\/0003-4819-94-4-454","journal-title":"Ann Intern Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-019-00651-1","article-title":"Effects of renal impairment on the pharmacokinetics of once-daily amantadine extended-release tablets","volume":"33","author":"deVries T","year":"2019","unstructured":"deVries T, Dentiste A, Di Lea C, Pichette V, Jacobs D. Effects of renal impairment on the pharmacokinetics of once-daily amantadine extended-release tablets. CNS Drugs. 2019, 33:783-9. 10.1007\/s40263-019-00651-1","journal-title":"CNS Drugs"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/clinpract13040075","article-title":"Myoclonus secondary to amantadine: case report and literature review","volume":"13","author":"Rissardo JP","year":"2023","unstructured":"Rissardo JP, Fornari Caprara AL. Myoclonus secondary to amantadine: case report and literature review. Clin Pract. 2023, 13:830-7. 10.3390\/clinpract13040075","journal-title":"Clin Pract"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.50.5.1456","article-title":"Acute delirium after withdrawal of amantadine in Parkinson's disease","volume":"50","author":"Factor SA","year":"1998","unstructured":"Factor SA, Molho ES, Brown DL. Acute delirium after withdrawal of amantadine in Parkinson's disease. Neurology. 1998, 50:1456-8. 10.1212\/wnl.50.5.1456","journal-title":"Neurology"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.13828","article-title":"Amantadine-induced craniofacial myoclonus: distinctive iatrogenic dysarthria in Parkinson's disease","volume":"10","author":"Lin I","year":"2023","unstructured":"Lin I, Armengou-Garcia L, Sasikumar S, Kuhlman G, Fox SH, Lang AE, Espay AJ. Amantadine-induced craniofacial myoclonus: distinctive iatrogenic dysarthria in Parkinson's disease. Mov Disord Clin Pract. 2023, 10:1408-13. 10.1002\/mdc3.13828","journal-title":"Mov Disord Clin Pract"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.5334\/tohm.683","article-title":"Evolving concepts in our understanding and treatment of Holmes tremor, over 100 years in the making","volume":"12","author":"Hey G","year":"2022","unstructured":"Hey G, Hu W, Wong J, Tsuboi T, Burns MR, Ramirez-Zamora A. Evolving concepts in our understanding and treatment of Holmes tremor, over 100 years in the making. Tremor Other Hyperkinet Mov (N Y). 2022, 12:18. 10.5334\/tohm.683","journal-title":"Tremor Other Hyperkinet Mov (N Y)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.7916\/D8WQ033X","article-title":"Levodopa-responsive Holmes' tremor caused by a single inflammatory demyelinating lesion","volume":"5","author":"Katschnig-Winter P","year":"2015","unstructured":"Katschnig-Winter P, Koegl-Wallner M, Pendl T, Fazekas F, Schwingenschuh P. Levodopa-responsive Holmes' tremor caused by a single inflammatory demyelinating lesion. Tremor Other Hyperkinet Mov (N Y). 2015, 5:339. 10.7916\/D8WQ033X","journal-title":"Tremor Other Hyperkinet Mov (N Y)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.13501","article-title":"Clinical features, neuroimaging, and levodopa-responsiveness in Holmes' tremor: a video-based case-series with a review of the literature","volume":"9","author":"Mishra A","year":"2022","unstructured":"Mishra A, Pandey S. Clinical features, neuroimaging, and levodopa-responsiveness in Holmes' tremor: a video-based case-series with a review of the literature. Mov Disord Clin Pract. 2022, 9:805-15. 10.1002\/mdc3.13501","journal-title":"Mov Disord Clin Pract"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.4262-04.2005","article-title":"Amantadine inhibits NMDA receptors by accelerating channel closure during channel block","volume":"25","author":"Blanpied TA","year":"2005","unstructured":"Blanpied TA, Clarke RJ, Johnson JW. Amantadine inhibits NMDA receptors by accelerating channel closure during channel block. J Neurosci. 2005, 25:3312-22. 10.1523\/JNEUROSCI.4262-04.2005","journal-title":"J Neurosci"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/0303-8467(92)90006-o","article-title":"Amantadine as N-methyl-D-aspartic acid receptor antagonist: new possibilities for therapeutic applications?","volume":"94 Suppl","author":"Stoof JC","year":"1992","unstructured":"Stoof JC, Booij J, Drukarch B. Amantadine as N-methyl-D-aspartic acid receptor antagonist: new possibilities for therapeutic applications?. Clin Neurol Neurosurg. 1992, 94 Suppl:S4-6. 10.1016\/0303-8467(92)90006-o","journal-title":"Clin Neurol Neurosurg"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-017-1780-1","article-title":"Is nigrostriatal dopaminergic deficit necessary for Holmes tremor to develop? The DaTSCAN and IBZM SPECT study","volume":"124","author":"Gajos A","year":"2017","unstructured":"Gajos A, Budrewicz S, Koszewicz M, et al.. Is nigrostriatal dopaminergic deficit necessary for Holmes tremor to develop? The DaTSCAN and IBZM SPECT study. J Neural Transm (Vienna). 2017, 124:1389-93. 10.1007\/s00702-017-1780-1","journal-title":"J Neural Transm (Vienna)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/450334-amantadine-toxicity-mimicking-holmes-tremor-following-diuretic-dose-escalation-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T23:59:08Z","timestamp":1768435148000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/450334-amantadine-toxicity-mimicking-holmes-tremor-following-diuretic-dose-escalation-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,14]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.101555","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,14]]}}}